You should contact your GP to discuss stopping GLP-1 treatment if you are experiencing: Persistent or severe side effects that significantly impact your quality of life, such as ongoing nausea, vomiting, diarrhoea, or abdominal pain that does not improve with time or dose adjustment
By mimicking the effects of this hormone, GLP-1 medications can help individuals reduce their calorie intake and lose weight more effectively
Annals of Internal Medicine, 177(8), 10161027
Emerging evidence demonstrates that GLP-1 receptor agonists may provide significant benefits for liver health, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and its inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH)
Once-weekly GLP-1 injections such as semaglutide and dulaglutide can be administered at any time of day, but should be given on the same day each week for consistency
Novos once-daily oral Wegovy is under Food and Drug Administration review with a decision expected later this year, while Lillys orforglipron is set for regulatory submission by the end of the year and a potential launch in 2026
